Pay in 4 interest-free payments of $5.51 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
Accessed February 12, 2026
Both agents are in Phase III trials with potential availability within the next few years, assuming successful trial completion and regulatory approval
Uncommon but notable adverse effects include: Hypokalaemia (low potassium) can occur during initial treatment of severe megaloblastic anaemia, as rapid cell production consumes potassium
Both are commonly discussed in relation to tissue repair, musculoskeletal recovery, inflammation, and physical resilience
US$ 28.50
US$ 27.89
US$ 28.70
US$ 29.70
US$ 23.76
US$ 26.25
